

# Su M Lwin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3987874/publications.pdf>

Version: 2024-02-01

19  
papers

738  
citations

758635

12  
h-index

887659

17  
g-index

20  
all docs

20  
docs citations

20  
times ranked

1199  
citing authors

#	ARTICLE	IF	CITATIONS
1	Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2319-2321.	0.3	119
2	APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	91
3	Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02. <i>Nature Communications</i> , 2019, 10, 1150.	5.8	82
4	Melanin distribution in human epidermis affords localized protection against DNA photodamage and concurs with skin cancer incidence difference in extreme phototypes. <i>FASEB Journal</i> , 2018, 32, 3700-3706.	0.2	77
5	Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa. <i>JCI Insight</i> , 2019, 4, .	2.3	56
6	Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 447-454.	0.6	50
7	Mutations in PLOD3, encoding lysyl hydroxylase 3, cause a complex connective tissue disorder including recessive dystrophic epidermolysis bullosa-like blistering phenotype with abnormal anchoring fibrils and type VII collagen deficiency. <i>Matrix Biology</i> , 2019, 81, 91-106.	1.5	45
8	Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore Anchoring Fibrils in RDEB. <i>Journal of Investigative Dermatology</i> , 2016, 136, 284-292.	0.3	42
9	Beneficial effect of ustekinumab in familial pityriasis rubra pilaris with a new missense mutation in <i>CARD14</i> . <i>British Journal of Dermatology</i> , 2018, 178, 969-972.	1.4	38
10	Acne, quorum sensing and danger. <i>Clinical and Experimental Dermatology</i> , 2014, 39, 162-167.	0.6	35
11	Generation and Clinical Application of Gene-Modified Autologous Epidermal Sheets in Netherton Syndrome: Lessons Learned from a Phase 1 Trial. <i>Human Gene Therapy</i> , 2019, 30, 1067-1078.	1.4	27
12	EBGene trial: patient preselection outcomes for the European GENEGRAFT <i>ex vivo</i> phase I/II gene therapy trial for recessive dystrophic epidermolysis bullosa. <i>British Journal of Dermatology</i> , 2020, 182, 794-797.	1.4	19
13	The promise and challenges of cell therapy for psoriasis*. <i>British Journal of Dermatology</i> , 2021, 185, 887-898.	1.4	13
14	Semidominant GPNMB Mutations in Amyloidosis Cutis Dyschromica. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2550-2554.e9.	0.3	12
15	The potential of gene therapy for recessive dystrophic epidermolysis bullosa*. <i>British Journal of Dermatology</i> , 2022, 186, 609-619.	1.4	9
16	Ichthyosis Prematurity Syndrome. <i>JAMA Dermatology</i> , 2016, 152, 1055.	2.0	8
17	Tissue and Circulating MicroRNA Co-expression Analysis Shows Potential Involvement of miRNAs in the Pathobiology of Frontal Fibrosing Alopecia. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2440-2443.	0.3	8
18	Immediate global support is needed for Myanmar. <i>British Journal of Dermatology</i> , 2021, 185, 466-467.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Restoring type VII collagen in skin. Med, 2022, 3, 273-275.	2.2	0